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dffects of Motivation andMedication on
lectrophysiological Markers of Response Inhibition in
hildren with Attention-Deficit/Hyperactivity Disorder
adeleine J. Groom, Gaia Scerif, Peter F. Liddle, Martin J. Batty, Elizabeth B. Liddle, Katherine L. Roberts,
ohn D. Cahill, Mario Liotti, and Chris Hollis
ackground: Theories of attention-deficit/hyperactivity disorder (ADHD) posit either executive deficits and/or alterations in motivational
tyle and rewardprocessing as core to thedisorder. Effects ofmotivational incentives on electrophysiological correlates of inhibitory control
nd relationships between motivation and stimulant medication have not been explicitly tested.
ethods: Children (9–15 years) with combined-type ADHD (n 28) andmatched typically developing children (CTRL) (n 28) performed
go/no-go task. Electroencephalogramdatawere recorded. Amplitude of two event-related potentials, theN2 and P3 (markers of response
onflict and attention), weremeasured. TheADHDchildrenwere all stimulant responders tested on andoff their usual dose ofmethylpheni-
ate; CTRLs were never medicated. All children performed the task under three motivational conditions: reward; response cost; and
aseline, in which points awarded/deducted for inhibitory performance varied.
esults: There were effects of diagnosis (CTRL ADHD unmedicated), medication (on off), andmotivation (reward and/or response cost
aseline) onN2andP3amplitude, although theN2diagnosis effect didnot reach statistical significance (p .1). Interactionsbetweenmotivation
nd diagnosis/medicationwere nonsignificant (p .1).
onclusions: Motivational incentives increased amplitudes of electrophysiological correlates of response conflict and attention in children
ith ADHD, towards the baseline (low motivation) amplitudes of control subjects. These results suggest that, on these measures, motiva-
ional incentives have similar effects in children with ADHD as typically developing CTRLs and have additive effects with stimulant
edication, enhancing stimulus salience and allocation of attentional resources during response inhibition.eyWords:ADHD, electrophysiology,motivation, response inhibi-
ion, stimulant medication
ttention-deficit/hyperactivity disorder (ADHD) is a neu-
rodevelopmental disorder characterized by age-inappro-
priate levels of hyperactivity, impulsivity, and inattention.
hildren with ADHD exhibit a range of cognitive difficulties,
ncluding impaired inhibition of the prepotent motor response in
o/no-go and stop signal tasks (1,2), leading some to suggest a
entral role for response inhibition deficits (3). Impaired re-
ponse inhibition in ADHD is associated with underactivation of
fronto-striatal-thalamic circuit involved in cognitive control (4)
nd reduced amplitude of two event-related potentials (ERPs),
he N2 and P3 (5–8), which in healthy individuals increase on
rials requiring motor inhibition or conflict resolution (9,10).
Children with ADHD also show atypical regulation of moti-
ational state: they respond to rewards when they are delivered
mmediately and with regularity but are less sensitive to rewards
hat are delayed or intermittent (11,12). It has been suggested
hat deficits in higher cognitive functions in ADHD, including
esponse inhibition, conflict processing, and attention, are a
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oi:10.1016/j.biopsych.2009.09.029consequence of impairments in the self-regulation of arousal and
motivational state (13,14). This raises the interesting question of
whether incentives given to enhance motivation will improve
inhibitory performance in children with ADHD. With the excep-
tion of two studies (15,16), most behavioral studies examining
this hypothesis have argued in favor of independence of inhib-
itory and motivational deficits (17–24). However, methodological
weaknesses limit their interpretation, including the absence of a
baseline (no or low motivation) (17,20); the presentation of
baseline and/or motivated conditions in a fixed order such that,
even after counterbalancing, order effects were uncontrolled and
not always equivalent between groups (19,21,22); and baseline
and motivational conditions delivered in separate sessions or
hours apart, potentially weakening the context provided by the
baseline (23). Another important question, which to our knowl-
edge has not yet been explored, is whether there are effects of
motivation on covert measures of neural function.
We investigated effects of motivation on neural correlates of
response conflict and attention in ADHD using a go/no-go
paradigm, in which two motivational conditions and a baseline
(low motivation) condition were presented repeatedly, random-
ized within session. Electroencephalography (EEG) data were
collected while children performed the task; amplitudes of N2
and P3 were measured. We predicted significantly smaller N2
and P3 amplitudes in the ADHD group than the control group.
Incentives were delivered continuously and immediately. We
therefore predicted that if inhibitory deficits are related to
impaired motivation in ADHD, incentives would significantly
enhance amplitudes of the ADHD group to at least the same
level as the baseline (low motivation) amplitudes of the control
group.
In addition, we investigated relationships between stimulant
medication (methylphenidate [MPH]) and motivation in the
BIOL PSYCHIATRY 2010;67:624–631
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M.J. Groom et al. BIOL PSYCHIATRY 2010;67:624–631 625DHD group using a within-subjects design. Methylphenidate is
elieved to increase availability of dopamine in the striatum,
nhancing salience of task-relevant stimuli (25,26), improving
nhibitory performance (27–29), and normalizing latency (30)
nd amplitude (31) of N2 and P3. It is currently unknown
hether other means of altering arousal, such as providing
otivational incentives, have similar effects on neurocognitive
unction as those produced by stimulant medications, and there
s relatively little research investigating the effects of medication
n such correlates. If motivational incentives and stimulant
edication produce complementary effects on neural correlates
f response inhibition, this would provide some support for the
ombined use of medication and behavioral reinforcement in the
reatment of ADHD. Although this approach was supported by
nitial findings of the Multimodal Treatment Study of Children
ith ADHD (MTA) (32) with lower medication doses required for
ymptom control in children receiving combined medication and
ehavioral management, there have, as yet, been no explicit,
ublished comparisons of the effects of motivational incentives
nd methylphenidate on neural correlates of inhibitory control. If
edication and motivation act synergistically, N2 and P3 ampli-
udes will be differentially larger in children with ADHD in the
igh-motivation conditions when medicated than when unmedi-
ated. Alternatively, each intervention may result in independent
mprovements in neural functioning.
ethods andMaterials
Participants were 28 children with ADHD (27 male partici-
ants), aged 9 to 15 years, and 28 typically developing control
ubjects matched on age, gender, and socioeconomic status
SES). Ethical approval was granted by the Multicentre Research
thics Committee (MREC). Informed written parental consent
nd verbal participant assent were obtained from all participants.
Table 1. Clinical and Demographic Characteristics of C
CTRL (n 28)
Mean SD
Age 12.54 1.81
IQ 104.93 14.31
SDQ
Hyperactive 1.68 1.70
Conners
DSM-Hyperactive 43.64 3.27
DSM-Inattentive 43.65 3.22
DSM-Total 44.25 3.32
ADHD-RSc
Off medications — —
Onmedications — —
Order of Testingd
Off medications first 13
On medications first 15
ADHD, attention-deficit/hyperactivity disorder; ADH
Revised (Long Form) ADHD index; CTRL, control group
Disorders; IQ, intelligence quotient; SDQ, Strengths and
aIndependent-samples t test comparing control gro
bPaired-samples t test comparingoff andonmedicat
26 participants who completed both the off and on med
cScores on the DuPaul ADHD Rating Scale were conv
dOrder of testingwas counterbalanced and randomi
were never medicated but were assigned to the same or
pairwise-matched.able 1 summarizes demographic and clinical information.Recruitment of ADHD Participants
Figure 1 presents recruitment information. Children with a
diagnosis of ADHD were referred to the study by child psychi-
atrists and pediatricians. An initial telephone interview screened
for broad inclusion and exclusion criteria, before an in-depth
assessment in person using the following measures: Strengths
and Difficulties Questionnaire (SDQ) (33); Conners Rating Scale-
Revised (Long Form) (34); Development and Well Being Assess-
ment (DAWBA), a semistructured clinical interview (35); and
Social Communication Questionnaire (SCQ) (36). With the ex-
ception of the SCQ, which was administered to parents only, all
were completed by parents and teachers. This, along with the
child’s medical notes, formed the basis for a consensus diagnos-
tic conference involving C.H. and another experienced child and
adolescent psychiatrist. Only cases with a confirmed diagnosis of
ADHD-combined subtype and an established clinical response to
MPH were included, unless they met one of the following
exclusion criteria: comorbid diagnosis (or symptoms above a
specified threshold) of tic disorder, pervasive developmental
disorder, learning disability (IQ 70) assessed using the Wech-
sler Abbreviated Scale of Intelligence (37), and neurological
disorder. Children with comorbid anxiety disorder, oppositional
defiant disorder (ODD) (n  13, 46%), and conduct disorder
(n  8, 29%) were not excluded.
Recruitment of Control Participants
Letters detailing the study were sent via local schools to
parents. Right-handed children with no psychiatric diagnosis
were selected for further assessment if they matched demograph-
ically a member of the ADHD group. Exclusion criteria were
those listed above for the ADHD group in addition to score 5
on the hyperactivity subscale of the SDQ and/or score 1 SD
above normative means on the Conners Rating Scale-Revised
d ADHD Groups
ADHD (n 28) Comparison
Mean SD t (df 54) p
12.51 1.75 .07a .946
90.86 11.71 4.027 .001
9.00 1.66 16.32a .001
84.96 7.23 25.37a .001
73.50 7.96 18.36a .001
81.61 7.69 23.62a .001
70.08 4.24 2.92b .004
64.31 10.51
13
15
, ADHD-Rating Scale-IV; Conners, Conners Rating Scale-
, Diagnostic and Statistical Manual of Mental Health
ulties Questionnaire.
TRL) and ADHD group.
ores in theADHDgroup; this analysiswas conductedon
on sessions.
to t scores using published population percentiles (38).
ithin the ADHDgroup. Participants in the control group
f testing as the ADHD participant with whom they wereTRL an
D-RS
; DSM
Diffic
up (C
ion sc
icati
erted
zedw(Long Form) ADHD index. Anxiety, depression, and conduct
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wroblems were not excluded, although no control subjects met
riteria for these disorders.
aradigm
The paradigm was a modified version of the visual go/no-go
ask, programmed using E-Prime (version 1.1, Psychology Soft-
are Tools). Stimuli were presented centrally on a color monitor
ositioned approximately 57 cm in front of participants. Inter-
timulus interval (ISI) was randomly jittered between 2.8 and 3.8
ec; stimulus duration was 100 msec. Participants were instructed
o fixate on a central point and press a response button (Cedrus
uperlab button box, Cedrus Corporation, San Pedro, California)
ach time a frequent “go” stimulus appeared and to refrain from
esponding to an infrequent “no-go” stimulus. There were 600
rials in total with 150 (25%) no-go trials, presented in three
ifferent motivational conditions (200 trials per condition). The
aradigm was presented in the context of a “space” theme; go
timuli were green aliens measuring 43-mm height by 40-mm
idth; no-go stimuli were black aliens of equal size. Participants
ere encouraged to “catch” as many green aliens as possible
hile avoiding catching the black aliens. A time limit (reaction
ime [RT] cap) was imposed on go trials: participants lost 1 point
or each slow or missed response (visual feedback given 1000
sec poststimulus) and gained 1 point for each timely response.
To minimize between- and within-subject variance in inhibi-
ion rate, the RT cap was dynamically altered throughout the
xperiment by a tracking algorithm. Prior to the start of the
xperiment, participants performed a practice session compris-
ng 20 go trials, which used a staircase procedure to identify the
igure 1. Flow chart showing recruitment and assessment of participants in
utism Spectrum Disorder; ERP, event-related potential; fMRI, functional mhortest time within which they could respond. This value
ww.sobp.org/journalbecame the lower bound of the tracking algorithm during the
main experiment (floor RT). The initial value of the tracking
algorithm for each motivational condition was set at this value
plus 200 msec. This RT cap was altered dynamically, based on
performance on no-go trials: following failed inhibits (FI), the
cap increased by 25 msec to improve the chance of success on
the next no-go trial; each successful inhibit (SI) resulted in a 25
msec decrease. There was an upper bound of 900 msec for all
participants.
Motivational Conditions
Participants performed the go/no-go task in three different
motivational conditions: baseline (low motivation); reward; and
response cost. In the baseline condition, participants gained or
lost 1 point following each SI or FI, respectively. In the reward
condition, 5 points were given for each SI; in the response cost
condition, 5 points were deducted for each FI. Thus, in the
baseline condition, the value attached to inhibiting on a no-go
trial was equal to that of responding quickly on a go trial. In the
motivated conditions, the value attached to successfully inhibit-
ing on a no-go trial was greater than the value attached to
responding quickly on a go trial, resulting in relatively greater
incentive to inhibit.
Stimuli were presented in five blocks, with each motivational
condition randomly presented once within each block. At the
end of each condition, a visual display detailed how many points
had been lost and gained for go and no-go trials. At the end of
each block, instructions emphasized either the need to withhold
rol (CTRL) and attention-deficit/hyperactivity disorder (ADHD) groups. ASD,
ic resonance imaging.contresponses to the no-go or make timely responses to the go
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M.J. Groom et al. BIOL PSYCHIATRY 2010;67:624–631 627timulus, depending upon whether participants achieved 50%
uccessful inhibitions during the block.
Inhibition rates are presented in Table 2 and demonstrate the
uccess of the algorithm in minimizing between-subject and
etween-session variance in inhibition rate. Because of the
racking algorithm, this index was blunted as a behavioral
easure of inhibitory control. The median value of the RT cap for
ach condition was used as an alternative index: the lower the
edian cap, the harder the participant was trying to inhibit. To
orrect for between-subject and between-session differences in
verall response speed, the floor RT was subtracted from the
edian cap for each condition, yielding the RT cap  floor
ifferential. To assess the effect of motivational incentives on
articipant behavior, a rating scale was administered at the end
f each testing session, asking the children to report which
ondition they “liked the most” and which condition made them
most careful.” The frequency with which each condition was
hosen in each group and session was scored.
edication Effects
Participants in the ADHD group performed the go/no-go
aradigm once on and once off their usual methylphenidate dose
order counterbalanced within the group). For the off medication
ession, they were required to stop taking their medication 36
ours beforehand. Group mean methylphenidate dose was 1.11
SD  .42) mg/kg. Symptoms were assessed each time using the
uPaul et al. (38) ADHD-Rating Scale-IV; Table 1 shows a
ignificant decrease in symptoms on medication compared with
ff medication.
rocedure
Participants attended on two separate days, each consisting of
n EEG session and a functional magnetic resonance imaging
fMRI) session (not reported here), with the order of testing
able 2. Descriptive Data for Behavioral Measures and ERP Amplitudes in C
CTRL
(n 28)
Mean
T Cap Floor Differential (msec) Baseline 328.92 18
Reward 264.18 17
Response Cost 235.17 17
nhibition Rate Baseline 39.57 1
Reward 46.50 1
Response Cost 44.86 1
2 Go Trials (V) Baseline 9.37
Reward 9.30
Response Cost 9.02
2 No-Go Trials (V) Baseline 12.16
Reward 12.47
Response Cost 12.13
3 Go Trials (V) Baseline 3.56
Reward 4.03
Response Cost 4.17
3 No-Go Trials (V) Baseline 6.10
Reward 6.37
Response Cost 6.14
Values for inhibition ratemustbe interpreted in the context of the trackin
etween-session differences in the ratio of failed to successfully inhibited n
ADHD, attention-deficit/hyperactivity disorder; CTRL, control group; ERPounterbalanced and held constant across the 2 days. Attention-deficit/hyperactivity disorder participants were tested off and on
medication; control subjects were never medicated but were
tested twice to control for practice effects. Control (CTRL) and
ADHD groups were pairwise matched on sociodemographic
variables and on the order in which each pair completed EEG
and fMRI testing. In between-group statistical analyses, the
off-medication session of each ADHD participant was compared
with the equivalent session of their matched control subject. Data
from two participants in the ADHD group who did not complete
the off-medication ERP session were excluded from analysis; the
control participants with whom they were matched remained in
the analysis to increase power.
Electrophysiological Data Recording
Data were collected using a Biosemi Active II System (Bio-
semi, Amsterdam, Netherlands) with 128-channel montage of
silver/silver chloride (Ag/AgCl) electrodes, sampled at 256 Hz.
Additional electrodes were placed at the inner orbital ridge and
the outer canthus of each eye to record eye movements and on
each mastoid to record other artefacts. During data collection,
voltage signals were referenced to an electrode placed to the left
of electrode Cz.
Electrophysiological Data Processing
Analysis was performed using Brain Vision Analyzer (BVA)
1.05 (Brain Products, Munich, Germany). After removal of noisy/
flat channels, data were re-referenced to the average reference
and filtered using .5 Hz high-pass and 30 Hz low-pass zero-phase
shift Butterworth filters with slope of 24 dB per octave. Data were
segmented into epochs, 2800 msec in length, with a prestimulus
period of 650 msec. Large epochs were created at this stage to
improve reliability of ocular correction, conducted using a
regression method (39). Epochs with activity exceeding100 V
or less than 2.5 V for more than 500 msec within an epoch were
nd ADHD Groups
gnosis Medication (n 22)
ADHD
(n 23)
ADHD Off
Medication
ADHD On
Medication
Mean SD Mean SD Mean SD
337.94 171.91 339.34 166.28 280.70 213.96
237.46 165.45 240.48 159.96 208.54 184.56
244.67 165.72 254.11 169.32 247.75 208.71
39.08 15.23 39.08 15.23 44.54 18.34
47.23 15.60 47.23 15.60 51.31 17.05
45.23 13.57 45.23 13.57 47.08 15.83
7.92 3.83 7.74 3.74 9.65 3.56
8.82 3.71 8.83 3.84 9.79 3.69
8.17 3.49 7.87 3.36 9.48 3.88
9.69 4.56 8.83 3.36 9.47 3.81
10.25 3.91 9.57 3.32 10.47 3.59
9.36 4.14 8.87 3.88 10.51 3.89
2.10 2.73 2.15 2.78 4.15 2.86
2.24 2.57 2.24 2.63 4.73 2.98
2.53 2.85 2.52 2.92 4.48 2.67
3.86 3.50 3.89 3.58 6.04 3.66
4.46 3.95 4.46 4.04 6.74 3.41
4.54 3.70 4.42 3.74 6.09 3.67
rithmemployedwithin theparadigmthatminimizedbetween-subject and
trials.
nt-related potential; RT, reaction time.TRL a
Dia
SD
2.05
2.68
5.18
5.53
3.14
3.08
4.15
4.22
3.96
4.64
5.03
4.75
2.44
2.56
2.60
3.49
3.58
3.72
galgo
o-goexcluded. Baseline correction was performed using a 200 msec
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wrestimulus reference period. Stimulus-locked epochs (200 to
000 msec peristimulus window) were averaged for the follow-
ng trial types within each motivational condition: go (go trials
ith response within 100 to 900 msec of stimulus onset); no-go
all no-go trials). A number of participants in both groups
CTRL  16; ADHD off medication  20; ADHD on medica-
ion  15) had too few SI trials (20) for reliable ERP averaging.
o avoid losing participants with insufficient trials, ERPs were
easured in the no-go waveform, collapsed across SI and FI
rials. A number of statistical procedures (Supplement 1) were
erformed to ensure this does not confound investigation of the
xperimental hypotheses.
Peak detection was performed using a semiautomated proce-
ure in which peaks were detected automatically by the BVA
oftware and checked by an expert blind to group status,
ccording to the following criterion: N2 (maximal negative peak
n a 220–400 msec time window) at Fz and Cz; P3 (mean
mplitude in a 400–700 msec time window) at Cz and Pz. The
arly portion of the waveform often contained a negative shift; to
rovide a more reliable measure of N2 amplitude, the peak was
alculated as the difference in amplitude between the N2 and the
receding positive peak. The P3 was measured as mean ampli-
ude because in the majority of datasets, the activity in this time
indow occurred over a long time period and it was frequently
ifficult to identify one specific peak.
tatistical Analysis
All analyses were conducted in two parts: first, effects of
iagnosis were investigated by comparing the CTRL group with
he ADHD group off medication. Second, effects of medication in
he ADHD group were investigated by comparing the off and on
edication sessions within subjects. In both analyses, motivation
as a within-subjects factor with three levels (baseline, reward,
nd response cost). Analysis of ERP amplitudes included a
ithin-subjects factor trial with two levels (go, no-go). Effect
izes (partial eta squared; p
2) are reported. Main effects and
nteractions significant at p  .05 (two-tailed) and trends (p  .1)
ere followed up with further analysis. Effects of motivation
ere investigated with planned Helmert contrasts comparing
otivated conditions (reward and response cost) with baseline
nd reward with response cost.
Five participants (two ADHD off medication; two ADHD on
edication; one ADHD both sessions) had fewer than 20 artifact-
ree no-go trials for ERP averaging and were excluded from
nalysis. Final sample sizes were 28 CTRL and 23 ADHD off
edication for diagnostic analyses and 22 ADHD participants for
edication analyses.
The data were checked for homogeneity of variance and
ormal distribution. Outliers (standard deviation greater than 2.5
rom group mean) were excluded. The data were checked to
nsure two female subjects in the sample (one ADHD, one CTRL)
ere not outliers; results remained robust to exclusion of these
articipants. All analyses described above were rerun with IQ
nd ODD diagnosis included as covariates. Neither were signif-
cant predictors in any analysis; the results are reported without
he covariates included.
esults
ffects of Motivation on Visual Analogue Scales
Participants responded to the motivational manipulations
ithin the paradigm, choosing the reward condition (CTRL:
1.1%; ADHD: 82%) above response cost (CTRL: 6.7%; ADHD:
ww.sobp.org/journal7.7%) or baseline (CTRL: 2.2%; ADHD: 10.3%) as the condition
they “liked the most.” Neither group (2  2.494, p  .1) nor
session (2  3.209, p  .1) affected these choices. Both groups
more frequently chose the response cost condition (CTRL: 81.8%;
ADHD: 72.5%) than either reward (CTRL: 18.2%; ADHD: 17.5%)
or baseline (CTRL: 0% ADHD: 10%) as the one that made them
“most careful” with no significant group (2 4.641, p .098) or
session (2  .082, p  .1) effects on these choices.
Effects of Motivation on Performance
Data for the RT cap  floor differential are shown in Table 2.
Statistical analysis conducted to investigate the effects of diagno-
sis and motivation on the RT differential revealed no effect of
diagnosis [F (1,52)  1, p
2  .001] but a significant effect of
motivation [F (2,104)  10.972, p  .001, p
2  .17] with smaller
mean differential in the motivated conditions (reward and re-
sponse cost) than baseline (p  .001). The diagnosis 	 motiva-
tion interaction was nonsignificant [F (2,104)  1, p
2  .009].
Analysis investigating the effects of medication and motivation
on the differential revealed no effect of medication [F (1,25)  1,
p
2  .03] but a significant effect of motivation [F (2,50)  7.569,
p  .001, p
2  .23], with smaller differential in the motivated
conditions than baseline (p  .006). The medication 	 motiva-
tion interaction was nonsignificant [F (2,50)  2.920, p  .1,
p
2  .07].
Effects of Diagnosis andMotivation on ERPMeasures
Event-related potential data relevant to all statistical analyses
are shown in Table 2. Event-related potential waveforms are
shown in Figure 2.
N2. Analysis revealed significantly greater amplitude on
no-go than go trials [F (1,49)  22.065, p  .001, p
2  .31] and
a main effect of motivation [F (2,98)  3.568, p  .032, p
2  .06]
with greater amplitude for reward than response cost (p  .005).
Group differences were in the predicted direction (CTRL 
ADHD) but did not reach significance [F (1,49)  2.723, p  .1,
p
2  .05]. The diagnosis 	 motivation interaction [F (2,98) 
1.111, p  .1, p
2  .022] and the diagnosis 	 motivation 	 trial
interaction [F (2,98)  1, p
2  .011] were nonsignificant.
P3. There were significant main effects of diagnosis [F(1,49) 
5.164, p .027, p
2 .1], trial [F (1,49) 33.364, p .001, p
2
.41], and motivation [F (2,98)  5.118, p  .008, p
2  .1] on P3
amplitude, with greater amplitude for CTRL than ADHD, for
no-go than go trials, and for reward and response cost compared
with baseline (p  .003). The diagnosis 	 motivation interaction
[F (2,98)  1, p
2  .008] and the diagnosis 	 motivation 	 trial
interaction [F (2,98)  1.254, p  .1, p
2  .025] were nonsignif-
icant.
Effects of Medication andMotivation on ERPMeasures
N2. One extreme outlier was excluded. Amplitude was
significantly greater on than off medication [F (1,20)  5.844, p
.025, p
2  .23] and for no-go than go trials [F(1,24)  5.298, p 
.03, p
2  .18]. There was a main effect of motivation [F (2,40) 
4.752, p  .014, p
2  .19] with greater amplitude in motivated
conditions than baseline (p  .045) and in the reward condition
compared with response cost (p  .036). The medication 	
motivation [F (2,48)  .621, p  .1, p
2  .03] and medication 	
motivation	 trial [F (2,48) 2.314, p .1, p
2 .09] interactions
were nonsignificant.
P3. Amplitude was significantly greater on than off medica-
tion [F (1,21)  24.490, p  .001,  2  .54] and for no-go thanp
go trials [F (1,21)  17.691, p  .001, p
2  .46]. There was a
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M.J. Groom et al. BIOL PSYCHIATRY 2010;67:624–631 629ain effect of motivation [F (2,42) 4.00, p .02, p
2 .16] with
reater amplitude in both motivated conditions compared with
aseline (p .007) and no significant difference between reward
nd response cost (p .1). The medication	motivation [F(2,50)
52, p .1, p
2 .02] andmedication	motivation	 trial [F(2,50)
.374, p  .1, p
2  .05] interactions were nonsignificant.
iscussion
This study investigated the effects of motivational incentives
nd medication on electrophysiological indexes of response
onflict and attention in children with ADHD. To ensure neural
orrelates were invoked to a similar degree in all children, a
racking algorithm minimized between- and within-subject vari-
nce in the ratio of failed to successfully inhibited no-go trials.
nalysis of the self-report visual analogue scales confirmed that
articipants responded to the motivational incentives: partici-
ants in both groups and sessions chose the reward condition as
he one they liked the most and the response cost condition as
he one that made them most careful. The success of the tracking
lgorithm and the motivational incentives was critical to assess-
ng effects of diagnosis, medication, and motivation on the ERPs.
ffects of Diagnosis andMotivation
In support of previous research, the P3, an index of attention
o a task-relevant stimulus (40) was significantly reduced in the
DHD group. N2 amplitude, an index of response inhibition (9)
r conflict detection/resolution (10), was reduced, although this
ell just short of statistical significance. Analysis revealed signifi-
ant increases in N2 and P3 amplitudes in both groups in the
otivated conditions compared with the baseline (low motiva-
igure 2. Stimulus-locked waveforms of CTRL group and ADHD group, off
ondition (center), and response cost condition (right).Within each panel, fr
ight. The top row shows go trials, and the bottom row shows no-go trials. S
edication; dashed line represents the ADHD group on medication. The w
rom the within-subjects medication comparison due to low trial numbers.ion) condition, indicating greater activation of processes under-lying response conflict and attention to a task-relevant (salient)
stimulus when the incentive to inhibit increased. Motivational
incentives enhanced amplitudes of the ADHD group, bringing
them closer to the baseline amplitudes of the control group.
There was no interaction between diagnosis and motivation. In
previous behavioral studies (17–23), the absence of interaction
has been interpreted as evidence of independence of inhibitory
and motivational deficits in ADHD, supporting the dual pathway
model (24). The present findings clearly show, however, that
motivational incentives were effective in enhancing electrophys-
iological markers of inhibitory control in ADHD, although the
effects were not differentially greater than in control subjects.
This suggests first that, in support of previous studies, the ADHD
children were neither hypersensitive nor hyposensitive to these
immediate, consistent incentives (12) and second that, to achieve
the same level as control children in both the baseline and
motivated conditions, children with ADHD may require incen-
tives that differ quantitatively or qualitatively from those that
produce effects in typically developing children. It will therefore
be important in future research to investigate other factors that
influence the effectiveness of incentives on inhibitory control in
ADHD, such as reward magnitude, reinforcement history, and
reinforcement scheduling (11,12). This may help clarify the
nature of relationships between inhibitory and motivational
deficits in this population. Of note, the diagnosis effect for the N2
did not quite reach statistical significance, possibly providing
insufficient scope for measuring relationships between this index
and motivation.
Effects of Medication andMotivation
Within-subjects analysis revealed significant effects of medi-
n medication. Panels show waveforms for baseline condition (left), reward
electrode (Fz) is shownon the left and central electrode (Cz) is shownon the
line represents the CTRL group; dotted line represents the ADHD group off
rm for the ADHD group off medication includes one participant excluded
, attention-deficit/hyperactivity disorder; CTRL, control.and o
ontal
olid
avefocation on N2 and P3 amplitudes, supporting the relatively limited
www.sobp.org/journal
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wesearch in this area (27–31) and identifying a possible locus for
he effects of methylphenidate on symptom severity. Interactions
ere statistically nonsignificant, suggesting that medication and
otivation have additive, rather than synergistic, effects on these
eural correlates. With regard to the MTA study, which reported
hat stimulant medication was effective at lower doses when
ombined with behavioral therapy (32), our findings suggest
hese interventions may act independently. Follow-up in the
TA revealed that behavioral treatment alone was less effective
han medication alone, a finding that is consistent with the larger
ffect sizes for medication than motivational incentives in the
resent study. Of course, the motivational incentives employed
ere were not designed to replicate behavioral modification
rograms used in clinical practice, but the results suggest that
oth operant conditioning (reward and response cost) and
timulant medication impact these particular electrophysiological
ndexes of response conflict and allocation of attentional re-
ources. It will also be important to determine whether the
ffects identified in the present study are generalizable to other
esponse inhibition paradigms and to children with less strin-
ently defined ADHD, including those with the inattentive
ubtype.
imitations
Although the sample sizes were large compared with many
ther ERP studies in this field (e.g., [5,7,17]), statistical power may
ave been insufficient to detect critical interactions. However,
everal methodological steps were taken to maximize power:
areful matching of samples on age, gender, and SES; conducting
nalysis on the equivalent session for each matched CTRL-ADHD
air; tracking algorithm to reduce between-subjects variance;
nd careful preprocessing of EEG data. Power calculations
evealed 79% power to detect an effect size of .4 and 84% power
o detect an effect of .3 for the diagnosis by motivation and
edication by motivation interactions, respectively. Nonsignifi-
ant interactions are therefore likely to be small. Low numbers of
uccessfully inhibited no-go trials meant it was not possible to
nvestigate neural correlates specific to successful inhibition.
revious studies have identified differences in the morphology of
he waveform on FI and SI trials, particularly with regard to the
mplitude and latency of the N2 and P3 (9,10). A number of
dditional analyses (Supplement 1) were conducted to ensure
hat collapsing across FI and SI trials does not confound inter-
retation of the effects of diagnosis, medication, or motivation
resented here.
onclusions
This is the first study to report effects of motivation on ERP
orrelates of response conflict and attention in children with
DHD. Stimulant medication also increased N2 and P3 ampli-
ude. Methylphenidate treatment and motivational incentives had
ndependent rather than synergistic effects on these ERP mark-
rs, with relatively greater effects of medication than motivation.
uture research should investigate under controlled conditions
hether the additive effects reported here for motivational
ncentives and stimulant medication in ADHD is replicated for
ehavioral and symptomatic outcomes.
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